Yahoo Finance host Brad Smith tracks today's top moving stocks and biggest market stories in this Market Minute, including ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Yields were mostly lower following reports that the economy fell into contraction in the first quarter and inflation readings ...

Mukhopadhyay took Mounjaro, an antidiabetic medication also used for weight loss, and saw dramatic results—losing 15 percent ...

Listen below or on the go on Apple Podcasts and SpotifyThis is an abridged transcript of the podcast.Companies looking to ...

Dave Moore, senior vice president of U.S. operations at Novo Nordisk, says his company wants to “meet patients where they are.” ...

Many Americans are taking GLP1 medications, which include weight loss and diabetes medications Ozempic and Wegovy.

A DAD once nicknamed “Fat Pal” by his friends has dropped five stone in five months after using Mounjaro. Sean Burns, 32, from Glasgow, said he has “struggled with excess weight” his whole life ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a ...

With President Trump's on-off tariffs causing huge uncertainty in recent weeks, some value stocks have been getting even ...

He also expects Lilly to have an early entry advantage over Novo’s Wegovy, which has the same active ingredient as its diabetes medicine Ozempic that is often used off-label for weight loss.